Skip to main content
Premium Trial:

Request an Annual Quote

Genome Technology s Lab Notebook: Reader Tips and Experiences: Feb 24, 2005

Following are scientist responses to the question, "What'syour top advice for designing a microarray-analysis experiment to ensure that your statistical analysis, control for error, and normalization procedures will give you an accurate end-answer?"

 

For a complete list of scientists' responses, read theNovember/December issue of Genome Technology, a GenomeWeb News sister publication.


"To be very honest, a large proportion of array experiments in the past were of very poor quality and no amount of clever statistical manipulation would give you good results (the  garbage in = garbage out principle). The array companies are putting out very good slides and our 'roll your own' are much more reliable now because of better printing instruments, substrates (slides), etc. I am going to enclose a couple of papers by Richard Simon at the NCI who is the expert in the questions you have asked: Journal of the National Cancer Institute, Vol. 95, No. 18, September 17, 2003, pp. 1362-1369; and BMC Bioinformatics 2003, 4:33, 02 September 2003. Also available here."

 

Ernest Kawasaki

Advanced TechnologyCenter

National Cancer Institute, NIH

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.